- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
199
PathoPhysiology oF rEnal oBstrUction
Renal Functional Changes |
|
|
During acute UUO, electrolyte and renal con |
||||||
|
|
|
|
|
|
||||
|
|
|
|
|
|
centrating ability is altered. Obstruction results |
|||
Renal Growth/Counterbalance |
|
|
in a significant decrease in sodium, potassium, |
||||||
|
|
and solute excretion. This results in a decrease |
|||||||
Hinman initially described compensatory gro |
in urine sodium concentration and an increase |
||||||||
in urine osmolality.28 |
However, during chronic |
||||||||
wth of the |
contralateral |
kidney in |
rats |
with |
UUO the literature is conflicting regarding the |
||||
UUO.16 Obstruction at a younger age is associ |
|||||||||
effects |
on electrolyte |
transport. With chronic |
|||||||
ated with a greater degree of ipsilateral growth |
|||||||||
UUO, sodium, potassium, and osmotic excre |
|||||||||
impairment |
and |
contralateral |
increased |
||||||
tion can either increase or decrease depending |
|||||||||
growth.17 It has also been demonstrated in neo |
|||||||||
upon the overall renal function and physiologic |
|||||||||
natal rats that an increased duration of obstruc |
|||||||||
homeostasis.17,2933 |
|
||||||||
tion results in a greater degree of growth in the |
Ureteral obstruction also results in decreased |
||||||||
contralateral |
kidney.18 |
Compensatory |
renal |
||||||
renal concentrating ability and urinary acidifi |
|||||||||
growth has also been demonstrated in human |
|||||||||
cation. The reduction in concentrating ability is |
|||||||||
fetuses.19 A greater degree of contralateral com |
|||||||||
thought to be a result of medullary and inner |
|||||||||
pensatory renal growth has been associated with |
|||||||||
cortical |
dysfunction |
caused by decreased |
|||||||
a greater severity of obstruction in infants with |
|||||||||
sodium absorption in the distal tubule and med |
|||||||||
ureteropelvic junction obstruction.20 |
|
|
|||||||
|
|
ullary nephrons.28 Under normal conditions, |
|||||||
|
|
|
|
|
|
one of the major tasks of the renal proximal |
|||
Vascular Changes |
|
|
|
tubule is acid secretion. The proximal tubule |
|||||
|
|
|
reabsorbs up to 90% of the filtered bicarbonate |
||||||
|
|
|
|
|
|
||||
High renal vascular resistance in the fetus and |
and can generate additional bicarbonate in |
||||||||
neonate is the result of activation of the renin |
order to regulate blood pH.34 Ureteral obstruc |
||||||||
angiotensin system (RAS).21 Chronic UUO |
tion causes urinary acidification dysfunction |
||||||||
results in increase of RAS activity and renal vas |
that may be secondary to alteration in the reab |
||||||||
cular resistance, which resolves by relief of the |
sorption of bicarbonate in the juxtamedullary |
||||||||
obstruction.22 Chronic UUO also results in vaso |
nephrons as well as decreased acid secretion in |
||||||||
dilatation of the contralateral kidney.23,24 The |
the distal tubules.28 |
|
|||||||
vasodilator nitric oxide plays a role in regulating |
Inflammatory Mediators |
||||||||
renal vascular resistance.After UUO,nitric oxide |
|||||||||
synthase activity is increased as a counterbal |
Interstitial inflammation is an early response to |
||||||||
ance to the increased renal vascular resistance |
|||||||||
brought about by RAS activation.25 |
|
|
UUO.35 This inflammation can contribute to |
||||||
|
|
|
|
|
|
tubular apoptosis and interstitial fibrosis.36 |
|||
Changes to Electrolyte Transport/ |
|
Monocyte chemoattractant protein1 (MCP1) is |
|||||||
|
believed to be a mediator of the intrarenal inflam |
||||||||
Renal Concentrating Ability |
|
|
mation that occurs after obstruction.37 MCP1 is |
||||||
Normally, the proximal nephron is responsible |
suppressed by heme oxygenase1 (HO1) that |
||||||||
provides negative feedback to this inflammatory |
|||||||||
for reabsorption of 60–70% of the filtered |
pathway.38 |
|
|||||||
sodium and water and 90% of the filtered bicar |
After renal obstruction, the upregulated |
||||||||
bonate.26,27 The thick ascending loop of Henle |
reninangiotensin system acts to recruit inflam |
||||||||
reabsorbs 20–30% of filtered sodium via |
matory cells through activation of AT1 and AT2 |
||||||||
sodiumchloride |
potassium cotransporters. |
receptors and the NFkBpathway.39 Angiotensin |
|||||||
Approximately, 5–10% of filtered sodium is |
also increases production of TGF1 and Smad3, |
||||||||
reabsorbed by the distal tubule through sodium |
which cause apoptosis and interstitial fibrosis.40 |
||||||||
chloride cotransport in the luminal membrane. |
|
|
|
||||||
As for water, the collecting duct can reabsorb |
|
|
|
||||||
10–15% of that filtered. Under normal condi |
Glomerular Development Changes |
||||||||
tions, urinary excretion of sodium and water |
|
|
|
||||||
can range from 0.1% to 3%, and 0.3 to 15% of |
There is irreversible nephron loss that occurs |
||||||||
the filtered load, respectively.26 |
|
|
with UUO in the developing kidney. Chronic |
|
|
200 |
|
|
|
|
|
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
|
UUO impairs nephrogenesis and glomerular |
UUO. In addition, fractional potassium excre |
||
development in both animals and humans.41 |
tion is also increased after release of BUO but |
||
Nephron number is decreased in fetal rabbits |
significantly decreased after release of UUO.28 |
||
and pigs that experience chronic UUO.42,43 Relief |
Figure 15.1 summarizes the differential |
||
of obstruction does not result in subsequent |
effects on renal blood flow and glomerular fil |
||
increased nephron development in the obs |
tration rate in unilateral and bilateral ureteral |
||
tructed kidney, but rather hyperfiltration in the |
obstruction. |
||
remaining nephrons.44 Hyperfiltration can result |
|
||
in injury to the remaining nephrons and future |
Limitations of Animal Models |
||
glomerular sclerosis even in the presence of a |
|||
|
|||
normal contralateral kidney.41,45,46 |
Much of the knowledge on the pathophysiology |
||
|
|
||
|
|
of renal obstruction is derived from animal |
|
Mechanical Stretch of Renal Tubules |
models. Although animal models have greatly |
||
|
|
enhanced the understanding of renal injury, |
|
Mechanical stretching of renal tubules is a sig |
they have limitations.52 Effective treatment of |
||
nificant step in the progression of obstructive |
acute renal failure in animal models has not |
||
nephropathy.47 Integrins are cell surface recep |
translated to successful outcomes in human.53 |
||
tors that can sense extracellular mechanical sig |
This may be secondary to the variations in |
||
nals and transmit them across the cell |
pathophysiology between humans and animals. |
||
membrane.48,49 After mechanical stretch occurs, |
For instance, in acute tubular necrosis, animals |
||
cation channels are activated with leads to Ca2+ |
have different locations of necrosis as compared |
||
influx.47 Increased calcium levels result in the |
to humans.52 Overall, animal models of obstruc |
||
activation of several pathways that lead to |
tion and / or renal damage that are more trans |
||
increased TGFb1 expression and induction of |
latable to the human condition are needed. To |
||
oxidative stress, which ultimately results in renal |
better assess the applicability of a particular |
||
inflammation and fibrosis.47 |
animal model of renal injury, applications such |
||
|
|
as the quantitation of excreted proteins or the |
|
Unilateral Versus Bilateral |
assessment of renal oxygenation by radiographic |
||
imaging techniques may be utilized to test the |
|||
There are major differences in renal function |
efficacy of the animal model.52 |
||
|
|||
before and after release of UUO and bilateral |
|
||
ureteral obstruction (BUO).28 During UUO and |
Future Research |
||
BUO,GFR decline occurs secondary to a decrease |
|
||
in intraglomerular capillary pressure. However, |
Current and future research efforts continue to |
||
with BUO a persistent elevation in intratubular |
focus on understanding the basic pathophysiol |
||
pressure occurs that also contributes to GFR |
ogy of UUO in an attempt to identify potential |
||
decline.50 Although kidneys with both forms of |
new therapeutic targets to protect or improve |
||
obstruction experience an initial increase in |
renal function. For example, it was believed that |
||
intratubular pressure, kidneys with UUO expe |
the antioxidant therapies had limited effect on |
||
rience a return to baseline intratubular pressure |
mitochondria, the primary source of intracellu |
||
within 24 h. However, BUO kidneys have persis |
lar reactive oxygen species, and previous |
||
tently elevated intratubular pressure even after |
attempts at using antioxidant therapies to miti |
||
24 h.50 Another difference with BUO is that |
gate the effects of UUO have had disappointing |
||
intravascular increases of atrial natriuretic pep |
outcomes. However, recently, Mizuguchi et al. |
||
tide and prostyacyclin occur that do not occur |
demonstrated that peptides,which protect mito |
||
with UUO.51 |
chondria in vitro can provide protection from |
||
After the release of obstruction, kidneys |
renal damage in a UUO model.54 This and other |
||
with BUO experience a postobstructive diure |
research are encouraging and will hopefully |
||
sis and natriuresis that does not typically occur |
identify new pathways of investigation. |
||
with UUO. Urinary concentrating ability is |
Other research efforts on UUO have focused |
||
decreased and fractional sodium excretion is |
on identifying new biomarkers of renal obstruc |
||
increased with release of BUO versus release of |
tion to help guide therapy and potentially |
201
PathoPhysiology oF rEnal oBstrUction
Unilateral
RBF: ¯Raff¯TG feedback
~GFR: ¯Raff Reff PGC PT
PGE2, angll, ET
RBF: Reff shift to inner cortex
GFR: PT PGC
RBF: Raff
GFR: ¯PGC ~PT
Angll, ET
RBF: Raff(angll, TXA2, ET)
GFR: ¯¯PGC¯PT [diuresis]
Urine flow, FENa; ¯FEK
¯Acidification, transporters, AQP offset by contralateral retention
Actue phase (1–2 h)
Mid phase (2–5 h)
Later phase (24 h)
Postobstruction +24 h
Bilateral or solitary
®RBF: Raff
GFR: PT ~PGC
Sympathetic nerve activity
RBF: Reff less flow shift
GFR: PT
RBF: Reff
GFR: PT ~PGC
Systemic vasoactive factors
RBF: Reff ~Raff
GFR: ~PGC PT
( angll, ET, TXA2, ANP, ¯NO)
Urine flow, FENa, FEK, ECV, ANP, urea
¯ Acidification
Figure 15.1. differential effects on rBF and gFr in UUo and BUo (reprinted with permission from Pais et al.66 copyright Elsevier 2006).
identify novel therapeutic targets. Previous efforts to identify markers of obstruction have focused on studying one or a few potential markers in a subjective fashion. Recently, in an effort to identify new biomarkers or panels of disease biomarkers, many researchers are turn ing toward Proteomics as a rapid unbiased screening tool for identifying new targets of interest. Evaluating proteins using proteomic technologies has the ability to increase the understanding of protein / protein interaction, protein modification, and protein interaction in the context of systems biology. As an example of expanding the use of animal models, a tem poral interrogation of the normal postnatal rodent urinary proteome demonstrated dra matic changes in the urinary proteome secon dary to physiologic changes related to neph rogenesis and developmental maturation.55 This work identified a potential set of proteins
that may indicate normal development; may provide the basis for future studies on renal development or renal dysfunction; and allow for future comparative studies in rat renal obstruction models. One significant study on human urinary obstruction using proteomics has been reported. In this study, a portion of the urinary proteome of children with hydro nephrosis (e.g., polypeptides < 30 kDa) were analyzed using various proteomic techniques. Using discoverybased proteomic methods, a potential polypeptide pattern was identified that may help determine which children require surgery.56 Further prospective validation work will determine the potential of these markers. In summary, these and other research efforts will hopefully further the understanding of obstructive nephropathy, and uncover new clinical significant markers and therapies for this disease.